The Promise of TKIs

Tyrosine kinase inhibitors may represent a new era for treatment of wet AMD and diabetic retinopathy.

By Omar Saeed, DO, MPH, Veeral S. Sheth, MD, MBA, FACS

Second-Generation Anti-VEGF Agents for Neovascular AMD

Newer agents have significantly altered the treatment landscape for nAMD.

By Scott D. Walter, MD, MSc, FASRS, Sharon Fekrat, MD, FASRS

Novel Therapeutics for Neovascular AMD

A variety of new agents aim to reduce treatment burden and preserve vision.

By Justin C. Muste, MD, Katherine E. Talcott, MD, FASRS

Treating Ophthalmic Artery Stenosis in Patients With AMD

A paradigm shift in the understanding of macular disease.

By Mario Saravia, MD, PhD, Pedro Lylyk, MD, Michael W. Calhoun, BSE, et al.

Refractive Error Management During Anti-VEGF Therapy

Addressing an overlooked opportunity for vision optimization in patients with DME or wet AMD.

By Eric A. Lovett Jr., BS, MBA, Matthew R. Starr, MD, Jason Hsu, MD, et al.

Addressing Socioeconomic Disparities in Vision-Threatening AMD

Targeted interventions can remove barriers to care.

By Ji Yun Han, BS, Sarishka Desai, BA, Nazlee Zebardast, MD, MSc, FRCSC

Reimagining the Patient Experience With a Streamlined Injection Protocol

Prioritizing patient comfort doesn’t have to come at the cost of efficiency and safety.

By Esther Lee Kim, MD

Upfront: Spring Is Here

Monthly reflection by Editor in Chief Diana Do, MD.

By Diana V. Do, MD

Uveitis Corner: Biosimilars in Noninfectious Uveitis

Many patients show similar outcomes after switching from the originator drug to a biosimilar, but further research is needed.

By Sruthi Arepalli, MD

Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.

By Elizabeth Cifers, MBA, MSW, CHC, CPC

Clinical Trial Update April 2025

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

36-Week Results From QUASAR

Results showed noninferiority of the 8 mg aflibercept groups compared with the 2 mg groups with a visual acuity gain of around 17 to 18 letters.

By Richard P. Gale, BSc, MBChB, FRCP, FRCOphth, MEd, PhD, Michael A. Singer, MD